Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II
- ACS Chem Biol. 2021 Nov 19;16(11):2164-2173. doi: 10.1021/acschembio.1c00067.
- 1. Department of Molecular Medicine, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
- 2. Department of Neuroscience, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
- 3. Albany Molecular Research Inc., 26 Corporate Circle, Albany, New York 12212, United States.
- 4. Laboratory of Molecular Physiology, NHLBI, National Institutes of Health, 50 South Drive, B50/3529, Bethesda, Maryland 20892-8015, United States.
Myosin IIs, actin-based motors that utilize the chemical energy of adenosine 5'-triphosphate (ATP) to generate force, have potential as therapeutic targets. Their heavy chains differentiate the family into muscle (skeletal [SkMII], cardiac, smooth) and nonmuscle Myosin IIs. Despite the therapeutic potential for muscle disorders, SkMII-specific inhibitors have not been reported and characterized. Here, we present the discovery, synthesis, and characterization of "skeletostatins," novel derivatives of the pan-myosin II inhibitor blebbistatin, with selectivity 40- to 170-fold for SkMII over all other Myosin II family members. In addition, the skeletostatins bear improved potency, solubility, and photostability, without cytotoxicity. Based on its optimal in vitro profile, MT-134's in vivo tolerability, efficacy, and pharmacokinetics were determined. MT-134 was well-tolerated in mice, impaired motor performance, and had excellent exposure in muscles. Skeletostatins are useful probes for basic research and a strong starting point for drug development.